Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Molecular Oncology
|
October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study
Chul S Ha, Joel E Michalek, Richard Elledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
JAMA Oncology
|
February 15, 2019
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial
Deborah W Bruner, Stephanie L Pugh, W Robert Lee, et al.
The Lancet. Oncology
|
February 12, 2011
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Jack Cuzick, Gregory P Swanson, Gabrielle Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2009
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008
Paul Okunieff, Lisa A Kachnic, Louis S Constine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Molecular Oncology
|
October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study
Chul S Ha, Joel E Michalek, Richard Elledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
JAMA Oncology
|
February 15, 2019
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial
Deborah W Bruner, Stephanie L Pugh, W Robert Lee, et al.
The Lancet. Oncology
|
February 12, 2011
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Jack Cuzick, Gregory P Swanson, Gabrielle Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2009
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008
Paul Okunieff, Lisa A Kachnic, Louis S Constine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
Page
of 6